CONTEXTUALIZING GENETICS FOR REGIONAL HEART FAILURE CARE

Pupalan Iyngkaran1, Merlin C. Thomas2, Renee Johnson3, John French4, Marcus Ilton5, Peter McDonald6, David L. Hare7 and Diane Fatkin8

1Flinders University, NT Medical School, Darwin Australia; 2Baker IDI Heart and Diabetes Institute, Melbourne Victoria 3004, Australia; 3Victor Chang Cardiac Research Institute; 4Liverpool Hospital, Sydney Australia; 5Darwin Private Hospital, Rocklands Drive, Tiwi, NT 0811; 6St Vincent's Hospital, Sydney, Professor of Medicine, UNSW, Head Transplantation Research Laboratory, Victor Chang Cardiac Research Institute and Visiting Cardiologist, Condobolin Aboriginal Health Service, Condobolin, NSW; 7University of Melbourne; Director of Heart Failure Services, Austin Health, Melbourne, Australia; 8Victor Chang Cardiac Research Institute, University of New South Wales

Abstract: Congestive heart failure (CHF) is a chronic and often devastating cardiovascular disorder with no cure. There has been much advancement in the last two decades that has seen improvements in morbidity and mortality. Clinicians have also noted variations in the responses to therapies. More detailed observations also point to clusters of diseases, phenotypic groupings, unusual severity and the rates at which CHF occurs. Medical genetics is playing an increasingly important role in answering some of these observations. This developing field in many respects provides more information than is currently clinically applicable. This includes making sense of the established single gene mutations or uncommon private mutations. In this thematic series which discusses the many factors that could be relevant for CHF care, once established treatments are available in the communities; this section addresses a contextual role for medical genetics.

Keywords: Congestive heart failure, genetics, indigenous australian, polymorphism, review, therapeutics.

INTRODUCTION

“I have three personal ideals. One, to do the day’s work well and not to bother about tomorrow. . . . The second has been to act the Golden Rule, as far as in my lay, towards my professional brethren and towards the patients committed to my care . . .”

William Osler 1849 – 1919 [1]

In many cases medical genetics may be tomorrow's solution, but it is today's question, and done correctly it is in our patient’s best interest. In two centuries, humanity has understood its hereditary biology and the factors that can change it. When Mendelian inheritance met Darwinist progressivity, we accepted chance genomic modification and gradual phenotypic evolution as our destiny. We also came to accept that we have no say in the process. A forgotten concept, introduced by the French biologist Jean-Baptiste Lamarck, where inheritance of acquired traits caused by changes in an environment can cause changes in behavior or characteristics leading to an increase or decrease of that phenotype both presently and in future generations, is taking off. His classic example was the stretching of the giraffe’s neck to reach treetops [2, 3]. While that extreme is probably unlikely, we have come to accept that he may not have been that far off the mark and that human-environment activity could also affect current and future biology.

In clinical cardiology many examples of genetics have shown increasing importance for pathophysiological explanations. The most common inherited mutations have gone on to explain inheritance patterns for many dilated cardiomyopathies. The more novel and the increasingly studied area of epigenetics have also found clinical correlations. It was noted that during the German introduce food embargo in western Holland, from the resulting famine, the consequent maternal nutritional deficiencies had intergenerational ramifications for mother, child and grandchildren. In Australia, CHF syndromes with comorbidities are epidemic among the Indigenous communities and at younger ages. Evidence continues to show little progress in declining CHF outcomes. It is thus important we give this area important consideration. Population studies have also identified patterns of CHF with different presentations, response to therapies, or pathophysiology with familial associations. These factors have been better illustrated in some communities such as Framingham and increasingly so from those with gene discovery programs [4-11]. The eventual goal for genetics studies would be to enhance “bench to bedside” (and beyond) translation that would allow early diagnosis and institution of preventative intervention to rein in the social and economic costs of
CHF [12]. In this review we explore genetic factors that could contribute to regional Australian CHF best practice*

CONTEXTUALIZING GENETICS FOR REGIONAL HEART FAILURE CARE

‘After 10 years of concerted effort, ..... clinical genetic testing ..... in cardiovascular disease is a work in progress. One reason is the complexity of the problem. The human genome is far more variable than originally suspected ..... is even more variable than it is now considered to be. With 3 billion bases in the genome, and over 5 billion people on the planet (that is 10 billion genomic copies), the mathematical probability is that every nucleotide in the genome is polymorphic in at least one living individual’. 

Gerald W Dorn II [13]

CHF care absorbs 1-2% of health budgets in developed nations. The vast majority of this relates to readmissions. In Australia there are several clear epidemiological patterns. There is an urban and rural divide, and an Indigenous and non-Indigenous divide. Many systems have explored service related themes to close this geographical divide. Some national and state data particularly from Western Australia have shown closing of geographical divides for many Australians but not Indigenous patients [14-17]. It is data like these that poses further questions on the pathophysiology for and contributors to the variations we see in treatment responses between groups.

The CHF syndrome essentially describes the phenomena where the heart or its support systems are unable to supply the body with adequate blood flow to meet metabolic requirements. The most common etiologies are loss of heart muscle from coronary artery disease, long term hypertension and increasingly diabetes, obesity and obstructive sleep apnea. Idiopathic cardiomyopathies are an important established cause in Europeans. In the Indigenous population, studies have noted an access burden at very young ages [17]. There is a high burden of rheumatic heart diseases [18], renal failure, diabetes and most other important comorbid conditions contributing to CHF, in addition to modifiable risk factors such as smoking and alcohol [19, 20]. It will thus be difficult to tease out what is an inherited condition or a predisposition. From the Framingham database one in five cases of HF was potentially heritable [8]. It is thus worth exploring these factors and contextualizing it for a more heterogeneous population.

Cardiovascular genetics has systematically explored most within the pathophysiological pathways. The most established science are Genome identification, in the nucleus and now more recently the mitochondria (both organelles containing DNA). This information has relevance predominately for inherited Mendelian genetics or sporadic mutations, and usually identified as single nucleotide polymorphisms (SNPs). Cardiomyopathies, chanellopathies, vascularopathies and indirect contributors such as familial hyperlipidemias and metabolic syndromes are factors that can promote CHF [6]. Advancements have also identified supporting apparatus and their responses under extreme physiological stress. End organ effects of consequence, such as ventricular hypertrophy [21, 22], and pharmacogenomics, in particular adrenergic [13] and RAAS systems [23, 24] and other pharmacogenomic interactions [25-28].

The way genetics has been viewed in CHF has also evolved. Dorn has described the transition from early single gene theories such as the candidate gene theory, to newer hypotheses like the common disease-common variant arguments (cumulative small effects of numerous alleles). Importantly the multifactorial etiology of CHF has provided founders from which it is difficult to separate the true extent of the underlying inheritance. Thus in the most common CHF model, patients present with multiple contributors, some such a comorbidity which is also subject to their own genetic variations, potential environmental exposure, and from here about one in three have a genetic attributor [6, 29]. New technologies are allowing for deeper and broader exploration of the genome where explanation could vary again. Presently however, terms that have important clinical utility for describing the role of genetics include common (familial) gene polymorphisms, candidate genes, common (sporadic) CHF, risk-modifier or risk-attributable gene effects are clinically relevant for contextualizing CHF at the community level. We discuss three areas of importance.

GENETICS RISK ATTRIBUTORS FOR HEART FAILURE

CHF syndromes have a clear familial predisposition where in 20-30% this risk has one or more genetic contributors. Within this there are perhaps 2 quite distinct clusters, common CHF is more frequent and complex where genetics are not the principal factor. In this form the inheritance is often non-Mendelian as shown in the Framingham Heart Study where CHF risk increases from 1.69 to 1.72 if one or both parents are diagnosed [7]. True familial cardiomyopathies on the other hand develop usually as the result of one mutation, or in a small subset (5%) 2 or more [6]. Identification of these multifactorial determinants started predominantly with hypertrophic cardiomyopathies (HCM). In many of these cases there are unique phenotypes that can perhaps be diagnosed from the history and review of echocardiography that would attract a clinician’s attention [30]. There also an age-dependent expression which offers screening opportunities, in this case the early teens [31]. Autosomal dominance, variable penetrance and marked phenotypic heterogeneity are characteristics in familial variant. Genetic data has accumulated significantly. Sarcomeric mutations in myosin heavy chain 7 (MYH7) and myosin binding protein C3 (MYPBC3) account for more than 70% of cases, other components are cardiac troponin and light chains around 5%. In 30-40% non-sarcomeric mutations occur [32]. The evolutions of genetics in HCM are important to highlight as the accumulated knowledge has transformed to real clinical applications. The two most noticeable are screening and risk stratification. Offspring from affected parents have a 50% chance of acquiring the gene. Research labs now offer fee-for-service molecular diagnosis in greater than one in three, if there is a family history [30]. This cascade screening approach is only possible because of the accumulated knowl-
Dilated cardiomyopathies (DCM) manifest with typical syndromicfeatures of poor systolic function and a dilated left ventricle. In 3-4 cases of idiopathic DCM have a positive family history, suggesting a genetic basis. Labelling as idiopathic, where there is no clear etiology, has probably underestimated true familial cases, particularly when disease is subclinical in those family members. In 50% of familial cases relatives of probands will be affected and disease can be picked up early [36]. Since 1998 there have been over 40 genes identified, the majority inherited in autosomal dominant pattern that alter many aspects of the myocyte cytoskeleton and contractile apparatus. Only around 30% of cases will there be clear benefits for genetic testing. Unlike HCM most mutations here are low prevalence thus also making it difficult to clinically correlate the pathogenicity. Again the cumulative knowledge is increasingly showing clinical correlation for patient’s benefits. Arguments for cascade screening benefits to rule out our disease and commence prophylactic treatments are reported [37, 38]. New scoring systems for prophylactic implantable cardiac defibrillators when concern of conduction disease as with LMNA, desmosomal and SCN5A mutations could also be beneficial [36-44]. Similarly auto-antibodies, and perhaps immunity, can predict development of CHF where there is a family history [45]. Thus an important area that needs to be discussed is the role of environmental and other factors and its ability to alter the course for those who are genetically predisposed. We discuss this subsequently.

GENETIC RISK MODIFIERS OF HEART FAILURE

Unlike inherited cardiomyopathies modifiers of CHF do not contribute directly to CHF but do so in the presence of primary etiologies and in doing so alter the chronology, severity and thus prognosis. In isolation these genes usually have a weak effect. Variation in clinical response or disease progression despite institution of clinical best practice is perhaps the best example [46, 47]. We focus on three important areas where knowledge of these SNP’s has shown important clinical relevance.

Single Nucleotide Polymorphisms of Common Counterregulatory Pathways

Myocardial adrenergic receptor blockade is a mainstay therapy for CHF, and dampens the effects of the sympathetic nervous system (SNS). Mean resting heart rates are so critical that for every 5 beat per minute decrease the mortality risk of CHF is reduced by 18% [48]. Polymorphism of adrenergic receptors particularly, the B1 adrenergic receptor (AR), is the most important for cardiovascular hemodynamic modulation. In this regard polymorphism can be toxic by preventing adequate blockade of continuous catecholamine exposure or altering downstream G-protein coupled activity in the absence of catecholamine access. Of the many documented polymorphisms (Box 2), the 2 most studied are Arg389Gly and Ser49Gly variant [48, 49]. In the former and most well studied, human data shows a gain of function and progression of CHF that can be modulated by ββ. In a study of 2460 patients genetics profiles for β1-AR1 and G-protein kinase 5 (GRK5) responsible for regulating the signal, ββ treatment increased survival in Caucasians but not African Americans. For patients not taking ββ Arg389Gly was associated with reduced survival in Caucasians. GRK5 Leu41 was associated with increased survival in African Americans. All patients with Arg389Gly and GRK5 Gln41Gln polymorphism benefited from ββ. This study shows that polymorphisms in signaling pathways and not race can contribute to differences in ββ response [49]. In the β-blocker Evaluation of Survival Trial (BEST) with bucindolol, which also recruited a larger number of African American patients, there was surprisingly no difference between the study group and placebo. Sub-analysis which initially removed African American patients or stratified on genetics, Arg389Arg, revealed fewer adverse outcomes. Retrospective analysis suggested the Arg phenotype which is less prevalent in Caucasians is associated with greater noradrenaline lowering response with bucindolol [50, 51]. This was the first ββ CHF trial to highlight clinical significance for genetic variations. In African American patients the two most important ADRB1 polymorphisms are more common [52].

The second critical feedback factor is the renin-angiotensin-aldosterone-system (RAAS) which regulates blood pressure by fluid and electrolyte balance, in heart, kidney and blood vessels through its main effector angiotensin II (AT II), and aldosterone which acts as a potent vasoconstrictor of afferent arterioles and by increasing fluid resorption in distal nephrons respectively. The increased intraglomeruli pressure and salt and water retention contributes to Cardio-Renal-Syndrome (CRS) progression. Along with ββ, RAAS blockade has provided some of the most robust prognostic data for all classes and even prevention of CHF. The ACE gene insertion/deletion (I/D) polymorphism is among the most well studied. Patients with an I/D have higher circulating ACE levels. Prospective follow-up of 328 patients raised clinical correlations between ACE-D allele and, poor transplant free survival. The impact of the D allele does not appear however when treated with ββ [53, 54]. In 479 participants with CHF, the ACE-D allele was similarly associated with increased risk of events. ACE-I and ββ treatment had greatest effect on DD patients, and the D allele effect was blunt by higher ACE-I doses [55]. Several larger studies, with risk factors for CHF, Genetics of Hypertension Associated Treatment (GenHAT) study and Perindopril Protection Against Recurrent Stroke Study (PROGRESS) did not establish causality. A third study on ACE-I treated hypertensive participants showed a 10 year increased mortality risk stratified from greatest risk to lowest risk as DD, ID and II [56]. Similarly a meta-analysis showed that variations for this gene have importance for coronary artery disease [57], a contributor to CHF. Polymorphism of angiotensinogen (AGT) gene Met235Thr and A1166C of the AII type-1 re-
ceptor contribute to more than 50% in variability of circulating ACE [23, 24]. In a similar Rotterdam study, 4095 participants were investigated for MET235Thr polymorphism of AGT. Subject who took ACE-I with the Thr allele had an increase of myocardial infarction and stroke [58], which were not modified in a subsequent treatment study with ββ [59]. More variations were noted in a Chinese population in risk, genotypes posing risk and response to ACE-I [60]. Perhaps the most important step in RAAS pharmacogenomics was the Perindopril Genetic Association study (PERGENE) of 8907 from which a scoring system using three SNPs could identify benefit or harm with perindopril [61], which highlights a significant advancement in the field [24-26].

**Cytochrome P450 System**

There is a wide spectrum of response to medications between patients, and genetic factors could account for anything between 20-95% of this. The permutations for this are amplified when we factor in physical characteristics, intrinsic physiological changes with comorbidities and extrinsic socio behavioral characteristics of the patient including diet and other drug use. Genetic polymorphisms of cytochrome P450 enzymes (CYP1B, CYP2 A, B, C9, C19, D6, E, J; CYP4A; CYP 11) could lead to pharmacodynamics or pharmacokinetic factors leading to extremely slow, fast metabolizers and variations in response. In addition there many cytochrome enzymes identified in the heart and their levels are altered during stages of cardiac dysfunction. Enzyme levels in the liver can also be altered by CHF. These systems start having greater relevance when CHF increases severity or with other potential confounders. In these cases adverse drug interactions and events are possible and variations in compliance results. Notable examples are irbesartan, losartan, metoprolol, clopidogrel and simvastatin. The latter two are often prescribed in ischemic cardiomyopathies or when concerns of atherosclerotic risk exist [62-65]. Many ββ are substrates for CYP2D6 enzyme including the CHF class metoprolol and carvedilol. Metoprolol has greater dependency, 70-80% metabolism, for this pathway and patients can be classified as ultraextensive, extensive, intermediate, or poor metabolizers on the inherited number of functional allele. Around 10% of Caucasians are poor metabolizers, where adverse event rates could be as high as 5 fold [66]. Without overstating the effects, as some later studies no significant influence on efficacy or toxicity of drug [52], it is also important not to underestimate the significance in a regional context with service and monitoring shortfalls, and also where the luxury of low and slow titration is not there, variations may then affect compliance and outcomes. Advancements for several drugs are important examples to highlight. Approximately 15% of clopidogrel undergoes a series of oxidative steps by several enzymes of the CYP450 system to form the active component. In 2208 patients who suffered an acute myocardial infarction, patients with two loss of function alleles for CYP2C19 enzyme had higher event rate (2.5 vs 13.1; HR 1.98; 95% CI, 1.10-3.58) four times higher rate of a subsequent cardiovascular event following percutaneous coronary intervention [67]. Warfarin is primarily metabolized by CYP2C9. Several genotypes labelled *2 and *3 reduce enzyme activity by 30 and 80%, where homozygote patients require almost similar percentage reduction in maintenance doses. Actual genetic testing to guide dosing is in ongoing evaluation [52, 68].

**Modifiers with Direct or Indirect Comorbidity Associations**

Cardiac specific SNP’s can alter cardiac pathology in the presence of comorbidities and similarly common polymorphism causing disease in other organs (comorbidity) may have relevance for myocardial changes. These points have their greatest relevance for common DCM where the etiology is most frequently coronary vascular disease, hypertension or diabetes. Among 249 patients with renal disease, 40% on renal replacement therapies, there was a significant association between LV mass and Arg389 homozygotes and heterozygotes independent of therapies [69] highlights a case of renal disease accentuating CHF risk. Secondly are polymorphisms such as those in the nitric oxide pathways that may explain variations in diseases physiology for some groups e.g. A-HEFT trial [70]. As patient populations we are looking after have greater racial heterogeneity this is also important to consider.

**GENETICS IN INDIGENOUS AUSTRALIANS**

“In the Alice Springs paediatric ward, the vast majority of the 20 or so children are Aboriginal…..For families, a visit to the ward can mean a period of isolation from their community or time with relatives who live in Alice Springs or who also happen to be in the hospital. It may be an unwanted upheaval from relatively peaceful community life, or an urgent and welcome respite from upheavals at home…..The challenge, then, is to balance a paediatric perspective with an Aboriginal one…..We need to find ways through the gaps from several vantage points, with Aboriginal people leading the way back to their own health. Dr Marcel Zimmet [71]

CHF among Indigenous Australians is underexplored, but accepted to occur at younger ages, more severe, with greater comorbidities and leads to poorer outcomes. Among the most prevalent heritable risks are rheumatic heart diseases, metabolic syndromes, renal impairments and cardiovascular diseases. It is unclear if any single or more SNPs contribute directly, together predisposes or modifies the development of cardiomyopathies. It is also unclear if the susceptibility to conventional risks such as alcohol, cytotoxic agents are modified. Acquired risk factors including cigarette smoking, excess alcohol consumptions and certain recreational drugs are more prevalent. Aspects of CHF in the Aboriginal community have been explored in another publication within this theme [15, 72]. Aboriginal focused cardiovascular genetics research has been lacking. A Medline search ‘(Genetics, Population/ or Genetics, Medical/ or genetics.mp. or Genetics/’ or ‘(epigenetics.mp. or Epiogenomics/’ or ‘(Polymorphism, Genetic/ or polymorphism.mp)’ and ‘(indigenous or aboriginal).mp.’ reveal 1314 hits. Adding in the search to Indigenous Australians or Aboriginal Australians (Indigenous Australian or Aboriginal Australian).mp. reveals only 19 hits.
Genetic Cardiomyopathies, Risk Factors and Community Differentials

Of the few prospective CHF studies, the Heart of the Heart followed 436 Indigenous adults across six Aboriginal communities in Central Australia. The findings include from this younger cohort, age 44±14 years and 64% women were; CHF diagnoses in 5.3% (95% CI 3.2% to 7.5%) when only 35% were previously diagnosed; Asymptomatic CHF cases in 13% (95% CI 9.4% to 15.7%); risk factor prevalence included body mass index (BMI) ≥30 kg/m(2) 42%, hypertension 41%, diabetes mellitus 40%, coronary artery disease (CAD) 7% and history of acute rheumatic fever or rheumatic heart disease 7% [73]. When the authors specifically explored the determinants of disease with an extensive assessment of socio-demographic, psychosocial, cardiovascular and metabolic status it was noted that depression increases CVD risk two fold (OR 2.03; 1.07-3.88; p<0.05). Residence as remote, peri-urban and urban, contributed differently to risks of chronic kidney disease (39.7%, 37.2% and 18.2%) and diabetes (28.4%, 34.0% and 19.2%). The glaring findings are increased CHF at young ages, more risk factors with psychosocial and socioeconomic differentials [74].

With significant differentials, and in considering potential genetic variations and their significance it is worth contextualizing on a comment by Gerald Dorn "...is intrinsic human genetic diversity: of ~3 billion bases in the human genome, ~10 million may be expected to differ between any two individuals, in the form of single nucleotide polymorphisms (SNPs), DNA copy number variations (CNV) and rare mutations" [6]. There will be variations for a population separated between 40 -60,000 years, thus suitable strategies for what is collected and how it is interpreted is as important as getting information. Thus whether the factors are described as race based or otherwise it appears that the population associations and the environment are important for how genes traverse in communities. Starting with inherited cardiomyopathies, we would expect there to be racial differences as would be determined by index cases and subsequent autosomal dominant inheritances within that family and community, and purely by chance. There is no evidence however to suggest that Indigenous patients would be more predisposed than any other group. Excess of rheumatic cardiomyopathies are better explained by interactions between poor socioeconomic living conditions and increased genetic predisposition to cross reaction between group A streptococcus and cardiac connective tissues [75].

Sympathetic and RAAS System SNPs

β-AR SNPs are well reported in many populations. Some of these common SNPs are increasingly associated with variable ββ responses: bucindolol – potential genetic due frequency of 52, 76], carvedilol [77], atenolol [78] and metoprolol [25]. It is interesting to note the observations that African Americans may have a poorer responses to ββ and HF outcomes also correlates with may findings of greater prevalence of Arg389 alone and in association with ADRA2C [79] and Leu41Gln variant in GRK5 [49, 80]. Drug specific correlations are also reported as with bucindolol and perhaps carvedilol. With carvedilol data show that Arg389 homozygotes with CHF and atrial fibrillation have deficient chronic heart-rate-lowering response to moderate doses. Importantly the response to one agent need not extend to others, as shown with bisoprolol [81]. In another carvedilol treated HF study, a combination of genotypes had two fold increased mortality [82]. Metoprolol was studied in a South Indian population with β1-AR Ser49Gly polymorphisms. Here SNP altered cardiac response to exercise but not metoprolol [83, 84]. However African Americans were less responsive to metoprolol if they had a GRK4 L65 variant [85]. Several pooled studies have produced data with recommendations that Gly389 allele posed a risk for East Asians but protective in whites and Arg389 homozygotes has a significant association with positive ββ response however treatment with bucindolol and metoprolol could negatively impact survival and left ventricular ejection fraction [86, 87].

The RAAS are important contributors of CHF in Aboriginal patients. The RAAS role starts in-utero where fetal or placental insults lead to reduce nephron numbers. Systemic and intrarenal RAAS further contribute by promoting tubulointerstitial fibrosis. Higher preterm births, lower preterm weight and 404,000 fewer nephrons are realities in this community [88, 89]. The ACE gene insertion/deletion (I/D) polymorphism is at very low frequency of 2% in Australian Aborigines but occurring in 14% of Aborigines with ESRD, and higher incidences of albuminuria [90]. As a whole genetic polymorphisms in the RAAS system can contribute to different renal phenotypes of which there are many variations across racial/ethnic groups which can also then account for variations in renal function [91]. Other potentially significant SNPs include the TT genotype of A240T (rs4292) with 52.3% versus 13.7% in Caucasians, which is located in the promoter region and with increased ACE levels [88, 92]. Idiosyncratic factors like ACE-I induced cough and temperature sensitivity may also have a genetic basis [93, 94].

Are there Racial Differences in Disease Pathophysiology?

There is accumulating evidence of differences in risk factors and even potential pathophysiology in groups of people. The ACE D allele is relatively common in Caucasians and Asians compared to Indigenous peoples, but the proportion of Indigenous patients with the D allele and renal failure is uncharacteristic [88] as is the increased risk for IgA nephropathy in Asians but not Caucasians [95]. Other examples included: a significant elevation of the CV risk factor apoE4 allele in 155 Indigenous compared with 113 European patient’s [96], a lipid cluster also noted in Tibetan Aboriginals [97]; inheritance for a robust inflammatory response [95], where previously cardiac antibodies were shown to predict DCM development [45]; novel susceptibility genes in chromosome 3 and 8 where diabetes is six times the general prevalence of 7.5% [96]; and other differences as highlighted by migration and isolation [98-101]. To highlight clusters in communities, the Amish community of Caucasian Dutch origin, the SNP (rs220741) for cardiac hypertrophy gene was noted to contribute to a more progressive form of CHF [102]. Differences can also vary within races. Warfarin, which is required for atrial fibrillation with rheumatic or other cardiomyopathies, is metabolized via polymorphically expressed CYP2C8 or CYP2C9 enzymes, that demonstrate intra-ethnic differences among Chinese, Japanese East and South Asians, and also Caucasians from Europe or America,
altered by hypertension and the later among women particularly. Two genes NOS3 and ADD gene polymorphisms were associated with hypertension and left ventricular remodelling [70]. In Tibetan Aboriginals two genes NOS3 and ADD gene polymorphisms were associated with hypertension and the later among women particularly [111]. Similarly β1-AR polymorphism can affect LV remodeling, and both of these are more common in African Americans [114]. Among 3863 Swedish hypertensives eight novel blood pressure associated SNPs, showed no pharmacogenetic interactions for BP reduction with β-blockers, diltiazem or diuretics [115], while others SNPs did [116]. These differences in findings have led to guideline writers factoring genetic information, physiology with clinical findings for improvements to guideline based algorithms.

Heart Failure in Pregnancy and Epigenetic Considerations

Variations in phenotypes can be expressed and heritable regulated through modification of chromosomal components without alterations in the nucleotide sequence. Gluckman et al. has presented strong arguments for developmental plasticity citing examples in the obesogenic environment. Maternal and paternal inherited epigenetic changes, coupled with prenatal cues and neonatal environmental exposures could ultimately determine the risk of developing unfavorable adult phenotypic expressions [117-119]. Structural cardiac changes such as LVH and LVF through modulation of fetal genes and suppression of adult genes requires gene reprogramming that is potentially transmissible [21, 120-122]. For mother’s rheumatic heart diseases and predispositions in developing peripartum cardiomyopathies, place risks on the child and mother and for future pregnancies [123-125]. For children programming starts early with higher incidences of low birth weight, preterm delivery, infection exposure and higher risk cardiovascular pregnancies [88]. This is a complex area that also requires consideration in longer term planning particularly in developing a mechanism to monitor patients.

TRANSLATING KNOWLEDGE INTO CLINICAL PRACTICE

“plus ça change, plus c’est la meme chose—the more things change, the more things stay the same”.
French Saying

There is an increasing pool of information on genes specific for CHF and those contributing to its risk. There are however permutations in interactions for which the clinical patterns are not always obvious. Thus genetics for CHF is a field where scientific advancements and clinical correlations have not often occurred at the same pace. There are some important points we can consider when looking to contextualize this for the populations we are looking after (Box 1):

| Stage | Strategy |
|-------|----------|
| Stage 1 HF risk | • Are there potentially significant acquired or inherited genetic confounders in the CHF clientele?  
• Is it greatly modifiable by optimizing current guideline based care? |
| Stage 2 Markers | • Are there simple means to identify the population at risk and is the evidence base robust?  
• Are new markers required?  
• Are these markers to identify an existing pathology or predict risk of future pathology? |
| Stage 3 Modulators of Cardiac Impairment | • Are there potential confounders to positive outcomes should pharmacological therapies be delivered effectively?  
• Are genetic polymorphisms a reasonable consideration? |
| Stage 4 Future Generations Risk | • Are there system wide risks to patients and their community?  
• Are these genetic and if so Mendelian Inherited or acquired inheritable? |

Importance of Clinical Correlations – Inference or Knowing?

Several models for studying inheritance of CHF including genome wide analyses from a cohort or population studies correlating clinical findings to subsequent genetic studies have both contributed to the area. Genome wide association studies have shown: in 1179 DCM and 1108 controls two new polymorphic [126]; in 200,000 hypertensive of European descendents highlighted sixteen novel loci from which a genetic risk score which correlated with phenotypes was derived [127]; in a multidisease study of 2,000 individuals with one of 7 major diseases and 3,000 controls, 24 independent susceptibility sites conferring risk with were identified [128]. In population from the cohort in the Framingham study a hereditary bases for the CHF risk LV hypertrophy and mass was inferred [129]. This association was inferred to be greater among African American than Caucasian patients in the Hypertension Genetic Epidemiology Network (the HyperGEN) study with 1664 participants [130]. Among 445 American Indian families and 1373 participants a substantial proportion of the difference of left ventricular dimensions and mass was inferred to be heredity [131] pointing further to racial for cardiac structural changes. Attempts to identify genetic variants 12,612 participants of purely European an-
As a collective we have not found the best ways to utilize stellation of high value targets prior to large studies. The opportunity to associate several important factors together. The situation of polypharmacy, poor follow-up and uncertain risk factor interaction with disease. We are increasingly encountering patients who have disease patterns and response to therapies that seem to vary from the norm. The value of improving on existing risk scoring systems, preventing adverse drug reactions in principle adds value.

**Personalized Therapeutics for Heart Failure**

Clinical medicine is currently practiced using phenotypic information from patients. The fundamentals for personalized medicine are that no two individuals will respond similarly to pharmacological therapies. The clinical significance for both cases arises when the gradient of this difference is noticeably different, when standard guideline based algorithms are applied and thus causing the patient to be at risk of being undertreated or suffering an adverse event [136]. Fortunately this risk is low. Thus genetics for personalizing therapies are still at a distance. Genetics for screening and counselling is now well established. It has a different role and one that is more selective in CHF. This science is also encouraging for the use of prophylactic treatments but on the whole still requires planning on case by case bases. This area is likely to advance further. Obtaining genome wide information as a means to explain physiology or for retrospective correlations is not backed by any current science. The evidence we have presented does however highlight a contextual case for genetics in CHF care for vulnerable groups. What we have also come to understand from the information is that there are weak and strong genes. In the latter the diagnosis is clear, where preemptive treatment is not a cure and counselling may be relevant. In the former the correlation between genotype and clinical phenotype can vary quantitatively, qualitatively, and inconsistently within the entire makeup of the individual. This point highlights again that any such community study must be accompanied by a robust prospective epidemiological study, where there is forensic epidemiological mapping so that the dynamics of gene, environment and treatment can be truly understood and meaningful conclusions derived. From an earlier example we cited polymorphism of NOS3 and B1-AR which could impact on hypertension was studied in different settings but not together. The opportunity to associate several important factors went missing. Thus it would be of value to identify the constellation of high value targets prior to large studies.

**Making Sense of Genetics for Heart Failure**

As a collective we have not found the best ways to utilize genetics to provide the information we want. Box 2 provides some examples where positive findings can be used to tailor a regional direction. In summation three important points are worth considering:

a. **Cost – effectiveness and value:** If we look at the example from the Indigenous community, the status quo is a situation of polypharmacy, poor follow-up and uncertain risk factor interaction with disease. We are increasingly encountering patients who have disease patterns and response to therapies that seem to vary from the norm. The value of improving on existing risk scoring systems, preventing adverse drug reactions in principle adds value.

b. **Overstating risks:** The interindividual variability in disease risk, pathophysiology or susceptibility to interaction with disease modifier is the start of further differential in the inter-individual variability in response to pharmacotherapy which can be attributed to three main sets of factors: clinical (e.g., age, acquired diseases and body mass index), environmental (e.g., xeno-biotic-drug interactions) and genomic (e.g. genetic variants, gene expression level) [137]. Looking at one well studied example, myocardial hypertrophy has a physiological and pathological spectrum from which we have many things to learn [138]. Thus all associations must be rigorously analyzed.

c. **Clear Treatment and Strategic Pathways:** Clinical correlation is the most significant step for cost effective genetic testing. These could be through several stages. In this regard planning to ensure sample sizes, power and correct collaborations so that knowledge translation can be smooth. In regards to some communities implications could have scientific and political policy consequences which could have effects on many unforeseen levels. These issues should be resolved early.

**CONCLUSION**

In this review we explored why considering genetics is important in some vulnerable groups. The translation of CHF therapies has not benefited all communities equally. Research in this field has also highlighted that some patients could benefit from therapies earlier, where others may not benefit at all. In addition we understand that this information can be represented as risk scores. This evolving field has made its greatest impact for understanding inherited cardiomyopathies, and at this stage allowed for genetic counselling for families. However with increasing knowledge that some communities such as the Indigenous Australians have poorer outcomes despite well-resourced health services, is an argument for widening the pool of knowledge. In this case we accept that increasing knowledge may not equate to immediate improvement in outcomes. However, the potential alone for this science to narrow gaps is an impetus for clinical researchers to initially hasten prospective audits to define potential disease clusters. This will allow for more focused questions to build a genetics program. Eventually it is hoped the combined data from other studies will build a pool of knowledge that will allow us to better plan treatments, with simplicity and enhance patient satisfaction and life expectancy.

**ABBREVIATIONS**

| Abbreviation | Definition                |
|--------------|---------------------------|
| AB           | Aldosterone Blockers      |
| ACE-I        | Angiotensin Converting Enzyme Inhibitor |
| AT           | Angiotensinogen           |
| AT I         | Angiotensin I             |
### Box 2. Genetic Modulation of Important Effectors in CHF.

| Effector Gene | Details | CV Risk | Polymorphisms* PHENOTYPE | c:B:A:H (%) | Notes |
|---------------|---------|---------|--------------------------|-------------|-------|
| AT (AGT)      | Precursor for AT - I | +    | M235T Inc AT levels & hypertension | ? | • More studies needed to define importance of variations in serum AT levels & AT II generation |
| Renin (REN)   | Cleaves AT to AT-II | +    | Hind III:Bgl I Probably adverse | ? | • More studies needed to define importance of variations in serum AT levels & AT II generation |
| AT – I (AGT1)| Precursor for AT - II | +    | ? | ? | ? |
| ACE (ACE)     | Cleaves AT-I to AT-II Hydrolysis of bradykinin | ++ | Ins/Del Intron 16 (I/D) 50% variation in serum ACE level | 40-48 37-43 58-70 | • Tissues ACE up to 2x higher DD>ID • Polymorphism can affect efficacy of multiple RAAS blockers |
| AT – II (AGT2)| Most potent effector Aldosterone production | +++ | Not Know | ? | • More studies needed of serum levels and health in some groups to guide future discussions |
| ATR (AGTR1/2)| 2 main receptors | +    | A1166 C Treatment resistant HT | 25 5 | • ATR-Type 2 not well studied • Irbesartan levels could be affected |
| Aldosterone   | Steroid hormone for fluid and BP regulation Potent Effector | +++ | CYP1B2 – key enzyme in biosynthesis ↑LV size/LVH | ? | • No know polymorphism of aldosterone gene |
| NKR (TACR 2) | Neurokinin. No mutation NK-1R. NK-2R probably relevant | | Gly231Glu:Arg375His Increase cough | ? | • Identify those benefit from ATRA first line |
| eNOS (NOS3)   | Key non-protein regulator of vascular health | +++ | Asp298Glu(Glu894Asp?) Unclear – probably not as significant on its own | 22 7 | • More studies of effects in association with other comorbidities and genetic alterations • Data on endothelial benefits of therapies could be expanded • Importance of psychosocial health on NO could be expanded |
| β1 (ADRB1)   | Inotropy, chronotropy Apoptosis and myocardial toxicity with prolonged stimulation | +++ | Arg389Gly: Ser49GLY Adverse Gain of function: Protective | 24:34-12-16 39:46:23-28 20-30:14 31-33:20-21 | • Regional prevalence probably worth exploring due to potential impact on CHF outcomes • Potential for lower efficacy of carvedilol not metoprolol. Other agents unclear. |
| β2 (ADRB2)   | Potential cardioprotection | +    | Gln27Glu:Gly16Arg Probably adverse | 25:39 19:49 9:51 | • Unclear if added information here would be a ‘game changer’ for regional HF care • High prevalence may suggest worth exploring |
| α1 (ADRA1D)  | Vasoconstriction | +    | T1848A:A1905G α1a Arg347/492Cys Unclear | 46:38 12:70 | • Unclear if added information here would be a ‘game changer’ for regional HF care |
| α2 (ADRA2C)  | Potential cardiotoxicity | +    | α2c Del322-325 Probably adverse | 4 43 | • Potential racial importance when combine with β1 polymorphisms as shown in Black patients. |
Myocyte failure leading to chronotropic and inotropic compensation is detected in the renal juxtaplomerular apparatus and adrenergic systems in the brain, adrenal and spinal column. SNS and RAAS chronically lead a cascade of events that increase blood pressure. These combined efforts are directly and indirectly toxic to cardiomyocytes. Adrenergic blockers and RAAS modulators (ACE-i, ARA, DRI, AB) block the effects of effectors with its receptors. Success is primarily related to the ability to bind the receptor. Genetic polymorphism can influence baseline tissue activity or drug efficacy. As the systems are heterogeneous and complex unwanted and unpredictable side effects can occur. It is important for us to explore the degree of diversity that exists to justify using therapies guided by physiological, pharmacodynamic and pharmacokinetic principles. The RAAS system contributes to numerous deleterious effects including hypertrophy, arrhythmias, cardiomyopathy, and CHF. Components of the RAAS system have defined genetic abnormalities that add additional risks.

Each pathway directly contributes to CV disease. (+) = more related to specific function. (++) Comprehensive effects including: direct contribution to diseases, symptoms and events (e.g. CHF, arrhythmias, LVH, atherosclerosis); (+++) More significant combinations of above factors, more aggressive progression of disease; A – Asian; AT – angiotensinogen; AGT-1 Angiotensin I; AT II-T2R; AT 11 T1R; B – African American/Black; C – Caucasian; CT – connective tissue; Del - deletion; DRI – direct renin inhibitors; GNBP - Guanine nucleotide-binding protein; H – Hispanic; LV – left ventricular; LVH – left ventricular hypertrophy; ROS – reactive oxygen species; WBC – white blood (Modified from Ref [6, 13, 15, 16])

### DISCLOSURES

All co-authors have won independent and governmental research funding. Several members provide counsel to pharmaceuticals. None pose a conflict of interest for this review.

### CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

---

### ACKNOWLEDGEMENTS

Declared none.

### REFERENCES

[1] Millard MW. Can Osler teach us about 21st-century medical ethics? Proe Bayl Univ Med Cent 2011; 24(3): 227-35.

[2] Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-63.

[3] Pray LA. Epigenetics: Genome, Meet Your Environment. As the evidence accumulates for epigenetics, researchers reacquire a taste for Lamarckism. The Scientist 2004; 18(13): 1.

[4] Watkins H, Ashrafian H. Inherited Cardiomyopathies. N Engl J Med 2011; 364: 1643-56.

[5] Bleumink G S, Schut A, Sturkenboom M, Deckers JW, van Duijn CM, Stricker BH. Genetic polymorphisms and heart failure. Genet Med 2004; 6(6): 465-74.

[6] Dorn GW, Marian AJ, Watkins H, Seidman C. The Genomic Architecture of Sporadic Heart Failure. Circ Res 2011; 108: 1270-83.

[7] Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 2006; 355: 138-47.

[8] Skrzynia C, Berg JS, Willis MS, Jensen BC. Genetics and heart failure: a concise guide for the clinician. Curr Cardiol Rev 2015; 11(1): 10-7.

[9] Cappola TP, Dorn II GW. Clinical Considerations of Heritable Factors in Common Heart Failure. Circ Cardiovasc Genet 2011; 4: 701-9.

[10] Roden DM, Johnson JA, Kimmel SE, et al. Cardiovascular Pharmacogenomics. Circ Res 2011; 109: 807-20.

[11] Wang L, McLeod HL, Weinshilboum RM. Genomics and Drug Response. N Engl J Med 2011; 364: 1144-53.

[12] Fatkin D. Familial dilated cardiomyopathy: Current challenges and future directions. Glob Cardiol Sci Pract 2012; 2012: 8.

[13] Dorn GW II. Adrenergic Signalling Polymorphisms and Their Impact on Cardiovascular Disease. Physiol Rev 2010; 90: 1013-62.

[14] McLean AS, Eslick GD, Coats AJ. The epidemiology of heart failure hospitalisation in Western Australia: a population-based study using data linkage. BMJ Open 2014; 4(5): e004724.
in the diagnosis and management of dilated cardiomyopathy and heart failure. J Am Coll Cardiol 2012; 60(4): 283-9.

[Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 2010; 12(11): 655-67.]

[Fortkin D, Orway R, Richmond Z. Genetics of dilated cardiomyopathy. Heart Fail Clin 2010; 6(2): 129-40.]

[Fortkin D; CSANZ Cardiovascular Genetics Working Group. Guidelines for the Diagnosis and Management of Familial Dilated Cardiomyopathy. Heart Lung Circ 2007; 16(1): 19-21.]

[Caforio AL, Mahon NG, Baig MK, et al. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007; 115: 76-83.]

[Talamah JA, Lanfare D. Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges. Curr Heart Fail Rep 2012; 9(1): 23-32.]

[Rodrin DM, Johnson JA, Kimmel SE, et al. Cardiovascular pharmacogenomics. Circ Res 2011; 109; 807-20.]

[Sweedberg K, Komajda M. The beat goes on: on the importance of heart rate in chronic heart failure. Eur Heart J 2012; 33(9): 1044-5.]

[Cresci S, Kelly RJ, Cappolla TP, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 2009; 54(5): 432-44.]

[Smart NA, Kwock N, Holland DJ, Jayasinge R, Giallauria FH. Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure. Clin Med Insights Cardiol 2011; 5: 55-66.]

[Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci USA 2006; 103: 11288-93.]

[Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy 2007; 27(6): 874-87.]

[McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103(12): 1644-8.]

[Le Groot P, Helbecque N, Limblin N, et al. Biphasic β-Adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. Eur J Heart Fail 2004; 6: 17-21.]

[McNamara DM, Holubkov R, Postava L, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004; 44(10): 2019-26.]

[Bleumink GS, Schut AF, Sturkenboom MC, et al. Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism. Pharmacogenet Genom 2005; 15: 75-81.]

[Agea WR, Jukema JW, Zwinderman AH, van der Wall EE. A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. Am Heart J 2002; 144: 760-8.]

[Scheltema H, Klungel OH, Witteman JC, et al. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet 2007; 15: 478-84.]

[Scheltema H, Klungel OH, Witteman JC, et al. Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis. Br J Clin Pharmacol 2007; 64: 57-66.]

[Su X, Lee L, Li X, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 2007; 115: 725-32.]

[Brugts JJ, Isaacs A, Boersma E, et al. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J 2010; 31: 1854-64.]

[Aspromonte N, Monitillo F, Puzzovio A, Valle R, Caldarola P, Iacovelli M. Modulation of cardiac cytochrome P450 in patients with heart failure. Expert Opin Drug Metab Toxicol 2014; 10(3): 327-39.]

[Chung JY, Yip VL, Pirmohamed M. Expanding role of pharmacogenetics in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2013; 13(3): 151-62.]

[Leach IM, van der Harst P, de Boer RA. Pharmacoge pinetics in Heart Failure. Curr Heart Fail Rep 2010; 7: 83-90.]

[Wheeler MT, Ho M, Knowles JW, Pavlovic A, Ashley EA. Pharmacogenetics of Heart Failure: Evidence, Opportunities, and Challenges for Cardiovascular Pharmacogenomics. J of Cardiovasc Transl Res 2008; 1: 25-36.]

[Fortkin D, Seidman CE, Seidman JG. Genetics and disease of ventricular muscle. Cold Spring Harb Perspect Med 2014; 4(1): a019063.]

[Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivetto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014; 64(1): 81-99.]

[Maron BJ, Maron MS. Hypertrophic cardiomyopathy. The Lancet 2013; 381(9862): 242-55.]

[Maron BJ, Maron MS, Semsarian C. Genetics of Hypertrophic Cardiomyopathy After 20 Years Clinical Perspectives. J Am Coll Cardiol 2012; 60: 705-15.]

[Marsiglia JD, Pereira AC. Hypertrophic cardiomyopathy: how do mutations lead to disease? Arq Bras Cardiol 2014; 102(3): 295-304.]

[Wordsworth S, Leal J, Blair E, et al. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J 2010; 31(8): 926-35.]

[Cannon L, Yu ZY, Marciniuc T, et al. Irreversible triggers for hypertrophic cardiomyopathy are established in the early postnatal period. J Am Coll Cardiol 2015; 65(6): 560-9.]

[Jacoby D, McKenna WJ. Genetics of inherited cardiomyopathy. Eur Heart J 2012; 33(3): 296-304.]

[Mahon NG, Murphy RT, MacRae CA, Caforio AL, Elliott PM, McKenna WJ. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 2005; 143: 102(3): 295-304.]

[Duboc D, Meune C, Lerebours G, Da Costa Martins PA, De Windt LJ. Regulation of fetal protein expression in heart failure. Expert Opin Drug Metab Toxicol 2014; 10(3): 25-36.]
Contextualizing Genetics for Regional Heart Failure Care

Current Cardiology Reviews, Vol. 12, No. 3

Zordoky BN, El-Kadi AO. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab 2008; 9(2): 122-8.

Belle DJ, Singh H. Genetic Factors in Drug Metabolism. Am Fam Physician 2008; 77(11): 1553-60.

Lilvis JH, Lanfear DE. Progress toward genetic tailoring of heart failure therapy. Curr Opin Mol Ther 2010; 12(3): 294-304.

Wurtke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metabolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429-37.

Simon T, Versuty C, Mary-Krause M, et al. Genetic determinants of response to elopregol and cardiovascular events. N Engl J Med 2009; 360: 363-75.

Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Eur J Clin Pharmacol 2009; 65: 365-75.

Stanton T, Inglis GC, Padmanabhan S, Dominiczak AF, Jardine AG, Connell JMC. Variation at the beta1-adrenergic gene locus affects left ventricular mass in renal failure. J Nephrol 2002; 15: 512-8.

McNamara DM, Tam SW, Sabinetis ML, et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail 2009; 360: 363-75.

Zimmet MD. Early impressions of paediatric health in Alice Springs: trying to see beyond the gaps. MJA 2010; 192(10): 606-7.

McGrady M, Krum H, Carrington MJ, et al. Heart failure, ventricular dysfunction and risk factor prevalence in Australian Aboriginal peoples: the heart of the Heart Study. Heart 2012; 98(21): 1562-7.

Brown A, Carrington MJ, McGrady M, et al. Cardiometabolic risk and disease in Indigenous Australians: the heart of the heart study. Int J Cardiol 2014; 171(3): 377-83.

Gray C, Thomson N. (2013) Review of acute rheumatic fever and rheumatic heart disease among Indigenous Australians. Retrieved [25-5-2015] from http://www.healthinfonet.ecu.edu.au/chronic-conditions/cvd/reviews/our-review-rhd

Kao DP, Davis G, Aleong R, et al. Effect of buccindol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail 2013; 15(3): 324-33.

Eschenhagen T. A frequent gene polymorphism affecting the heart-rate response to carbodilol. Pharmacogenomics 2013; 14(2): 115-8.

Wikoff WR, Frye RF, Zhu H, et al; Pharmacometabolomics Research Network. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One 2013; 8(3): e57639.

Smith KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347: 1135-42.

Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008; 14: 510-7.

Rau T, Dungan HD, Edelmann F, et al. Impact of the beta1-adrenergic receptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther 2012; 92(1): 21-8.

Petersen M, Andersson JT, Hjelvang BR, et al. Association of beta-adrenergic receptor polymorphisms and carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol 2011; 71: 556-65.

Ramu P, Mahesh Kumar KN, Shewade DG, et al. Polymorphic variants of beta 1 adrenergic receptor gene (Ser49Gly & Arg389Gly) in healthy Tamil volunteers. Indian J Med Res 2010; 132: 62-6.

Mahesh Kumar KN, Ramu P, Rajan S, Shewade DG, Balachander J, Sithan C. Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population. J Cardiovasc Pharmacol 2008; 52(5): 459-66.

Bhatnagar V, O'Connor DT, Brophy VH, et al; AASK Study Investigators. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens 2009; 22(3): 332-8.

Liu WN, Fu KL, Gao HY, Shang YY, Wang ZH, Jiang GH, et al. B1 Adrenergic Receptor Polymorphisms and Heart Failure: A Meta-Analysis on Susceptibility, Response to β-Blocker Therapy and Prognosis. PLoS One 2012; 7(12): e55111.

Tufa TB, Petros Z, Melke LF. Pharmacogenetics of β1Adrenergic Receptor Blockers in Heart Failure Therapy: A Systematic Review. Cardiov Pharm 2013; 2: 113.

Lumbers ER, Pringle KG, Wang Y, Gibson KJ. The renin-angiotensin system from conception to old age: the good, the bad and the ugly. Clin Exp Pharmacol Physiol 2013; 40(11): 743-52.

Ahluwalia TS, Ahuja M, Rai TS, et al. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. DNA Cell Biol 2009; 28: 141-50.

Lester S, Heatley S, Bardy P, et al. The DD genotype of the angiotensin-converting enzyme gene occurs in very low frequency in Australian Aboriginals. Nephrol Dial Transplant 1999; 14: 887-90.

Campbell CY, Fang BF, Guo X, et al. Associations between genetic variants in the ACE, AGT, AGTR1 and AGTR2 genes and renal function in the multi-ethnic study of atherosclerosis. Am J Nephrol 2010; 32: 156-62.

Zhu X, Bouzekri N, Southam L, et al. Linkage and association analysis of angiotensin-1-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet 2001; 68: 1139-48.

Kim TB, Oh SY, Park HK, et al. Polymorphisms in the neurokinin-2 receptor gene are associated with angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharm Ther 2009; 34(4): 457-64.

Hong YC, Kim H, Lim YH, Yoon JH, Kwon YM, Park M. Identification of RAS genotypes that modulate blood pressure change by outdoor temperature. Hypertens Res 2013; 36(6): 540-5.

Qin YH, Zhou TB, Su LN, Lei FY, Huang WF, Zhao YJ. Association between ACE polymorphism and risk of IGA nephropathy: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2011; 12(3): 215-23.

Tate J, Kesting JB, Marczak M, et al. Apolipoprotein E polymorphism in indigenous Australians: allelic frequencies and relationship with dyslipidaemia. Med J Aust 1999; 170(4): 161-4.

Zhang LX, Sun Y, Liang Y, et al. Relationship between Dyslipidemia and Gene Polymorphism in Tibetan Population. Biomed Environ Sci 2012; 25(3): 305-10.

Cox AJ, Moscovis SM, Blackwell CC, Scott RJ. Cytokine gene polymorphism among Indigenous Australians. Innate Immunity 2014; 20(4): 431-9.

Busfield F, Duffy DL, Kesting JB, et al. A genomewide search for type 2 diabetes-susceptibility genes in indigenous Australians. Am J Hum Genet 2002; 70(2): 349-57.

Huoponen K, Schurr TG, Chen Y, Wallace DC. Mitochondrial DNA polymorphism: evidence for genetic isolation and regional differentiation. Hum Immunol 2001; 62(9): 954-69.

Walsh SJ, Eckhoff C. Australian Aboriginal population genetics at the DISSO VNTR locus. Annals Hum Biol 2007; 34(4): 457-64.

Walsh SJ, Mitchell RJ, Watson N, Buckleton JS. A comprehensive analysis of microsatellite diversity in Aboriginal Australians. J Hum Genet 2007; 52(9): 712-25.

McEvoy BP, Lind JM, Wang ET, et al. Whole-genome genetic diversity in a sample of Australians with deep Aboriginal ancestry. Am J Hum Genet 2010; 87(2): 297-305.

Parsa A, Chang YP, Kelly RJ, et al. Hypertrophy-associated polymorphisms ascertainment in a founder cohort applied to heart failure risk and mortality. Clin Transl Sci 2011; 4(1): 17-23.

Garcia-Martin E, Martinez C, Ladero JM, Agundez JAG. Whole-genome analysis of microsatellite diversity in Aboriginal Australians. J Hum Genet 2007; 68: 1139-48. 1 Adrenergic Receptor Polymorphisms and Heart Failure: A Systematic Review.
[109] Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340: 609-16.

[110] Cohn JN. A-HeFT Old Dog, New Endothelial Tricks. Tex Heart Inst J 2005; 32(3): 366-8.

[111] Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Trial to Prevent Heart Attack (ALLHAT). Arch Intern Med 2008; 168: 207-17.

[112] Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks. An update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension 2010; 56: 780-800.

[113] Li K, Liang Y, Sun Y, et al. The Relationship between Polymorphisms at 17 Gene Sites and Hypertension among the Aboriginal Tibetan. Biomed Environ Sci 2012; 25(5): 526-32.

[114] McLean RC, Hirsch GA, Becker LC, Kasch-Semenza L, Gerstenblith G, Schulman SP. Polymorphisms of the beta adrenergic receptor predict left ventricular remodeling following acute myocardial infarction. Cardiovasc Drugs Ther 2011; 25(3): 251-8.

[115] Hamrefors V, Sjögren M, Almgren P, et al. Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms. J Hypertens 2012; 30(6): 1151-60.

[116] Liljedahl U, Kahan T, Malmqvist K, et al. Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. J Hypertens 2004; 22(12): 2321-8.

[117] Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of In Utero and Early-Life Conditions on Adult Health and Disease. N Engl J Med 2008; 359(1): 61-73.

[118] Gluckman PD, Hanson MA, Buklijas T, Low FM, Beedle AS. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat Rev Endocrinol 2009; 5: 401-8.

[119] Kaati G, Bygren LO, Edvinsson S. Cardiovascular and diabetes mortality determined by nutrition during parents' and grandparents' slow growth period. Eur J Hum Genet 2002; 10: 682-8.

[120] Papait R, Greco C, Kunderfranco P, Latronico MV, Condorelli G. Epigenetics: a new mechanism of regulation of heart failure? Basic Research in Cardiology, 2013;108(4):361, 2013.

[121] Movassagh M, Choy MK, Knowles DA, et al. Distinct epigenetic features in end-stage failing human hearts. Circulation 2011; 124(22): 2411-22.

[122] Papait R, Condorelli G. Epigenetics in heart failure. Ann N Y Acad Sci 2010; 1188: 159-64.

[123] Van Tintelen JP, Pieper PG, Van Spaendonck-Zwarts KY, Van Den Berg MP. Pregnancy, cardiomyopathies, and genetics. Cardiovasc Res 2014; 101(4): 571-8.

[124] Cemin R, Janardhanan R, Donazzan L, Daves M. Peripartum cardiomyopathy: moving towards a more central role of genetics. Curr Cardiol Rev 2013; 9(3): 179-84.

[125] González AM, Maceira BM, Pérez E, Cabrera VM, López AJ, Larruga JM. Genetics, environment, and diabetes-related end-stage renal disease in the Canary Islands. Genet Test Mol Biomarkers 2012; 16(8): 859-64.

[126] Villard E, Perret C, Gary F, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J 2011; 32(9): 1065-76.

[127] The International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478(7367): 103-9.

[128] Wellcome Trust Case Control Consortium (WTCCC). Genomewide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-78.

[129] Post WS, Larson MG, Myers RH, Galdersisi M, Levy D. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension 1997; 30(5): 1025-8.

[130] Arnett DK, Hong Y, Bella JN, et al. Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. Hypertension Genetic Epidemiology Network. Am J Hypertens 2001; 14(12): 1226-30.

[131] Bella JN, MacCluer JW, Roman MJ, et al. Heritability of left ventricular dimensions and mass in American Indians: The Strong Heart Study. J Hypertens 2004; 22(2): 281-6.

[132] Vasan RS, Glazer NL, Felix JF, et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA 2009; 302(2): 168-78.

[133] Arnett DK, Li N, Tang W, et al. Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study. BMC Med Genet 2009; 10: 43.

[134] Arnett DK, Meyers KJ, Devereux RB, et al. Genetic variation in NCAM1 contributes to left ventricular wall thickness in hypertensive families. Circ Res 2011; 108(3): 279-83.

[135] Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2002; 136(3): 181-91.

[136] Turner RM, Pirmohamed M. Cardiovascular pharmacogenomics: expectations and practical benefits. Clin Pharmacol Ther 2014; 95: 281-93.

[137] Pereira NL, Sargent DJ, Farkouh ME, Rihal CS. Genotype-based clinical trials in cardiovascular disease. Nat Rev Cardiol 2015; 12(8):475-87.

[138] Dorn II GW. The Fuzzy Logic of Physiological Cardiac Hypertrophy. Hypertension 2007; 49: 962-70.

[139] Schulze-Bahr E. Chap 17: Single Nucleotide Polymorphisms in Health and Cardiac Disease; Genetics, Mechanisms, Treatment, Prevention. Electrical Diseases of the Heart. 2008, pp 281-289. Ed Gussak I, Antzelevitch C, Wilde AAM, Friedman PA, Ackerman MJ, Shen WK. Springer Pub 2008. DOI: 10.1007/978-1-84628-854-8_18.
Author/s:
Iyngkaran, P; Thomas, MC; Johnson, R; French, J; Ilton, M; McDonald, P; Hare, DL; Fatkin, D

Title:
Contextualizing Genetics for Regional Heart Failure Care

Date:
2016-01-01

Citation:
Iyngkaran, P., Thomas, M. C., Johnson, R., French, J., Ilton, M., McDonald, P., Hare, D. L. & Fatkin, D. (2016). Contextualizing Genetics for Regional Heart Failure Care. CURRENT CARDIOLOGY REVIEWS, 12 (3), pp.231-242. https://doi.org/10.2174/1573403X12666160606123103.

Persistent Link:
http://hdl.handle.net/11343/260008

File Description:
Published version

License:
CC BY-NC